Loading clinical trials...
Loading clinical trials...
A Pilot Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Conditions
Interventions
[18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.
[18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.
Locations
1
United States
Stanford Hospital and Clinics
Stanford, California, United States
Start Date
May 1, 2017
Primary Completion Date
December 1, 2022
Completion Date
December 1, 2022
Last Updated
December 5, 2022
NCT05075980
NCT05815927
NCT06736379
NCT05329532
NCT05059444
NCT06823479
Lead Sponsor
CellSight Technologies, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions